SynAct Pharma AB Balance Sheet

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	53.41	61.21	62.4	108.25	24
Cash & Short-Term Investments	53.41	61.21	62.4	108.25	24
Cash Growth	-12.75%	-1.90%	-42.36%	351.08%	64.95%
Other Receivables	5.42	5.96	4.22	6.46	3.11
Total Trade Receivables	5.42	5.96	4.22	6.46	3.11
Other Current Assets	12.53	46.68	8.45	25.52	7.81
Total Current Assets	71.35	94	75.06	140.23	34.92
Net Property, Plant & Equipment	1.21	1.94	0.66	2.1	3.18
Other Intangible Assets	147.82	154.59	152.16	-	-
Long-Term Investments	0.14	0.14	0.14	0.27	0.27
Total Assets	220.52	270.52	228.02	142.6	38.37
Accounts Payable	9.49	17.35	9.67	4.72	4.25
Accrued Expenses	11.14	10.09	9.82	4.91	7.89
Current Portion of Leases	0.62	0.6	0.58	1	0.98
Other Current Liabilities	0.28	0.42	4.88	4.38	2.27
Total Current Liabilities	21.52	28.46	24.94	15.01	15.39
Long-Term Leases	0.6	1.29	0.06	1.06	2.11
Other Long-Term Liabilities	28.11	26.61	26.84	-	-
Total Long-Term Liabilities	28.7	27.89	26.89	1.06	2.11
Total Liabilities	50.23	56.35	51.83	16.08	17.5
Common Stock	6.67	5.81	4.45	3.71	3.25
Additional Paid-in Capital	835.34	763.12	646.57	394.84	193.6
Accumulated Other Comprehensive Income	12.11	18.24	15.77	2.77	-0.4
Retained Earnings	-683.83	-573	-490.6	-274.79	-175.59
Shareholders' Equity	170.29	214.17	176.19	126.52	20.87
Total Liabilities & Equity	220.52	270.52	228.02	142.6	38.37
Total Debt	1.21	1.88	0.64	2.06	3.09
Net Cash (Debt)	52.2	59.33	61.76	106.18	20.91
Net Cash Growth	-12.02%	-3.94%	-41.84%	407.85%	43.72%
Net Cash Per Share	1.02	1.16	1.90	3.85	0.81
Book Value	170.29	214.17	176.19	126.52	20.87
Book Value Per Share	3.33	4.19	5.42	4.59	0.81
Tangible Book Value	22.47	59.58	24.03	126.52	20.87
Tangible Book Value Per Share	0.44	1.17	0.74	4.59	0.81